UPDATE: Morgan Stanley Initiates Chimerix with Overweight on CMX001 Potential

In a report published Monday, Morgan Stanley analyst David Friedman initiated coverage on Chimerix CMRX with an Overweight rating and $26.00 price target. In the report, Friedman noted, “Chimerix is developing CMX001 for the prevention or treatment of a broad range of dsDNA viruses across various immunocompromised pt settings.Most data to date, which we find compelling, is in the first target indication - CMV prevention/treatment in HSCT. However, we expect a broader reach for this drug over time. Importantly, we view this drug in the lead indication as having the properties of successful drugs: a) best in disease potential, b) makes an important impact on high acuity pts, and c) fulfills a clear unmet need.” Chimerix closed on Friday at $20.95.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!